Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

Objective: Evaluate the efficacy and safety of elagolix, a GnRH antagonist, to treat polycystic ovarian syndrome (PCOS). Design: A phase 2, multicenter, double-blind, randomized, placebo-controlled trial. Setting: Outpatient and academic medical centers. Patient(s): One hundred fourteen women with P...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Michael C. Snabes, M.D., Ph.D., Juki Ng, Pharm.D., Ph.D., Hong Li, Ph.D., Izna Ali, Pharm.D., Ph.D., Mohamad Shebley, Ph.D., William D. Schlaff, M.D
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	Elsevier 2023-06-01
श्रृंखला:	F&S Reports
विषय:	Polycystic ovarian syndrome elagolix menstrual cycle ovulation GnRH antagonist
ऑनलाइन पहुंच:	http://www.sciencedirect.com/science/article/pii/S2666334123000156
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!